Direct-compression antacid tablet manufacturing uses heavy magnesium carbonate for two simultaneous functions: it is the acid-neutralizing active ingredient, and it improves die fill density on a high-speed rotary tablet press. The material is recognized as an OTC antacid active under 21 CFR 331.11. Compendial identity is confirmed against Ph. Eur. 0042; the MgO assay is 40.0% to 45.0%. Before blending, the powder is passed through a conical mill fitted with a 0.6 mm rasp screen to break soft agglomerates. Loss on drying is measured by USP <731>; residual moisture above 1.0% is reduced by tray drying at not more than 70°C. The dried material is blended in a bin blender with mannitol, sorbitol, and magnesium stearate. Blend uniformity is tested during process validation by USP <905>, with an acceptance criterion of relative standard deviation not more than 5.0% for the initial validation batches. The blend is compressed on a rotary tablet press with a precompression station set at 5–8 kN and a main compression station set at 12–20 kN. Tablet hardness is monitored because basic magnesium carbonate exhibits elastic recovery after compression. Friability is assessed by USP <1216>; tablets that fail the limit are not reworked by simple recompression because the particle-size distribution shifts. Acid-neutralizing capacity is measured by USP <301> against the labelled dose. The tablets are packaged in HDPE bottles with desiccant canisters because moisture sorption causes surface roughness and slows disintegration during later shelf life. Production-scale failure modes include capping at high press speed, weight variation from poor hopper flow, and punch filming from hygroscopic fines.

What Determines Sedimentation Volume and pH Drift in an Oral Antacid Suspension?

For oral suspension, heavy magnesium carbonate is suspended in a structured aqueous vehicle rather than dissolved. Its aqueous solubility is low; therapeutic neutralization occurs after the suspension reaches gastric acid. The vehicle is prepared with microcrystalline cellulose and sodium carboxymethylcellulose as a co-processed dispersible excipient. Dispersion is carried out in a stainless steel mixing vessel with a bottom-sweep agitator and a rotor-stator homogenizer. The carbonate is added through a bag dump station with local exhaust, because the fine fraction has high dust potential. The pH is measured by USP <791>. The target pH is held in the range 8.5–9.5; above 9.5, ester-based flavour components hydrolyse and carbomer vehicles lose viscosity due to monovalent cation shielding. Viscosity is measured by a Brookfield viscometer using the spindle and speed defined in the validated method. Sedimentation volume is checked in a graduated cylinder. A structured vehicle with a yield stress above 0.5 Pa is required to keep the carbonate suspended; this value is measured by a rheometer with vane geometry. The batch is held for 24 h before final pH adjustment and filling. Microbial limits follow USP <61> and USP <62> for non-sterile oral liquid. The finished suspension is filled into amber PET bottles with child-resistant closures. The main production risk is pH drift during storage, which reduces suspension viscosity and changes sedimentation rate.

Hard-shell capsule lines running heavy magnesium carbonate as an antacid or mineral source require flow conditioning because the heavy grade has a relatively high bulk density but retains a cohesive fine fraction. The blend is prepared in a tumbling bin blender at fill volume 60% to 70% of rated capacity; higher fill volumes reduce the cascading zone and extend blend time without improving homogeneity. Flow properties are tested using USP <1174>; compressibility index and Hausner ratio are calculated from bulk and tapped density measured by USP <616>. For capsule filling, a compressibility index below 25% is the usual acceptance limit. If the neat carbonate exceeds this value, colloidal silicon dioxide is added at a level determined by a response-surface design, commonly not exceeding 2.0 wt%. Magnesium stearate is used at 0.25 wt% to 0.75 wt% in a final lubrication step. The capsule machine is configured with a dosator or tamping pin system; tamping pin pressure is reduced to avoid forming hard plugs in the powder bed. Fill weight is controlled by gravimetric check weighing every 15–30 min. The powder bed is maintained at room temperature below 50% RH. Empty capsules are conditioned at 25°C/40% RH to prevent dehydration-induced brittleness. The finished capsules are stored in cold-form aluminium blister packs if the product contains flavours or moisture-sensitive actives. Release testing for antacid capsules is based primarily on acid-neutralizing capacity rather than a single dissolution curve; the method is USP <301>.

Effervescent granule formation and acid-base stoichiometry for carbonate-driven release systems

Dry granulation is required for effervescent granules because heavy magnesium carbonate reacts with citric acid and tartaric acid after dissolution in water. The carbonate is the carbon dioxide source and the antacid buffer. Because the heavy grade is not anhydrous MgCO₃, stoichiometric ratios are calculated from the MgO content in Ph. Eur. 0042 rather than from the anhydrous molecular weight of 84.31 g/mol. The granulation line runs under controlled environment at 20–25°C and no more than 25% RH. Anhydrous citric acid with loss on drying below 0.5% is required. Roller compaction is used instead of wet granulation because aqueous binder would prematurely start the reaction. The compacted ribbon is milled through an oscillating granulator with a 1.0 mm screen. Free moisture in the finished granules is measured by Karl Fischer titration per USP <921> Method Ia; the release limit is not more than 0.5%. The granules are filled into single-dose sachets made of multi-layer foil. Seal integrity is tested by vacuum leak testing. The finished product is dissolved in water before oral administration. In this presentation, heavy magnesium carbonate provides acid-neutralizing capacity and carbon dioxide for dispersion and palatability.

During aqueous high-shear granulation of antacid powder sachets, heavy magnesium carbonate behaves as a moisture-absorbing alkaline solid rather than as an inert diluent. If the formulation contains acid-labile actives, the carbonate can provide local pH control in the granule liquid film. The granulation is run in a top-drive high-shear mixer with main impeller tip speed in the qualified range. Purified water or a binder solution of povidone K30 is added by peristaltic pump over several minutes. Water addition is stopped before the power draw curve reaches the capillary state plateau; overgranulation produces dense agglomerates that dry slowly and increase granule hardness. The wet mass is discharged through a wet mill with a 4–6 mm screen and dried in a fluid-bed dryer at inlet air temperature not exceeding 70°C. Drying time depends on batch size and binder level. Granule moisture after drying is monitored by USP <731>. The dried granules are sized through a 1.25 mm oscillating granulator screen. Particle size distribution is checked by sieve analysis per USP <786>; an excessive coarse fraction above 25% retained on the 500 µm sieve may cause segregation during sachet filling. The granules are filled into stick packs on a vertical form-fill-seal machine. Because the product contains a carbonate buffer, residual moisture in the finished granule must remain below the degradation threshold of oxygen-sensitive flavours. This wet granulation route is suited to oral powder sachets where the carbonate functions as both active antacid component and moisture-controlling granulation substrate.

If the target presentation is injectable, what conversion route is required?

If the target presentation is injectable, direct suspension of heavy magnesium carbonate for parenteral use is not a standard compendial preparation; the low aqueous solubility and particulate nature create embolic risk. The practical manufacturing route is chemical conversion. Heavy magnesium carbonate is reacted with dilute hydrochloric acid in a glass-lined or passivated stainless steel reactor to generate a magnesium chloride solution. The addition is made slowly because carbon dioxide evolution is rapid. The reactor temperature is maintained below 40°C during acid addition to control foaming. The reactor vent line is connected to a gas scrubber. The solution is then diluted with Water for Injection to a target magnesium concentration. The pH is adjusted to the final parenteral range, typically 5.5–7.5, using dilute hydrochloric acid or magnesium hydroxide. The solution is passed through activated carbon and a 0.22 µm sterilizing-grade filter. Bioburden is monitored before filtration per USP <61> and USP <62>. Bacterial endotoxin is measured by USP <85> or Ph. Eur. 2.6.14. The acceptance limit is set by the final product’s endotoxin limit based on route, dose, and body mass; the carbonate input must be selected from a dedicated parenteral-grade supply chain with low endotoxin and controlled heavy metals. The final sterile solution is filled and terminally sterilized by autoclaving or sterilizing filtration depending on container compatibility. Published direct-injection data for unmodified heavy magnesium carbonate suspension is limited; therefore, the conversion route is the only technically defensible application for injectable formulations.